Keeping Track Of Rolling Submissions: Gamida Cell, Roche, Lilly And Reata Are Latest To Use Fast Track

 
• By Bridget Silverman

Applications are underway for omidubicel, mosenutuzumab, pirtobrutinib and omaveloxolone.

Keeping Track Feature image

More from Approval Standards

More from Pathways & Standards